EORTC and The Movember Foundation bring TIGER trial to Europe

Germ cell tumors such as those that cause testicular cancer are often cured and treatment guidelines are well established, but still a small number of patients cannot be cured. They either relapse or develop a primary resistance to the prescribed first line chemotherapy and are subsequently treated with conventional or high dose chemotherapy with autologous stem cell transplant. However, it is unclear whether these approaches are the best route to take.

TIGER, led by the United States based Alliance for Clinical Trials in Oncology is a randomized phase III trial designed to compare conventional with high dose chemotherapy as first salvage treatment in men with relapsed or refractory germ cell tumors. If the high dose chemotherapy is shown to be more advantageous, then TIGER could well improve the survival of these patients and decrease the number of lines of treatment they must take to hopefully be cured.

The EORTC and the Movember Foundation are now working together to support the expansion of recruitment into the TIGER trial, EORTC trial 1407, within Europe. They invite suitably qualified and experienced research teams to express their interest in participating in this exciting new global initiative. The Expression of Interest for European researchers is funded by the Movember Foundation in support of their vision of having an everlasting impact on the face of men’s health. For its part and in line with its mission to improve the management of cancer and related problems, the EORTC will sponsor TIGER in Europe with the support of this expression of interest process.

Interested European researchers are invited to submit their expression of interest to participate in TIGER.

TIGER is funded in North America by the United States National Cancer Institute.

John Bean, PhD
EORTC, Medical Science Writer

Back to news list

Related News

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma